A Phase 4 interventional study of Peginterferon alfa-2a and Peginterferon alfa-2a in Hepatitis C, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.
Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phase 4, Interventional, and Treatment
This study will examine the effectiveness of low-dose peginterferon and ribavirin therapy for certain patients with chronic hepatitis C-a liver disease that, in some patients, can progress to cirrhosis of the liver, liver cancer, and liver failure.
Sixty patients with chronic hepatitis C infected with HCV genotype 2 or 3 will be treated using the combination of either low- or standard dose peginterferon and ribavirin for 24 weeks, with re-treatment using the standard doses and a longer duration (48 weeks) for those who do not respond to or relapse after initial low dose therapy.
Adult patients with chronic hepatitis C who have HCV genotype 2 or 3 and previously have not received anti-viral treatment will be given peginterferon alfa-2a (90 or 180 micrograms weekly by injection) and ribavirin (800 mg daily by mouth). Patients will be monitored at 2- to 4-week intervals for side effects, compliance, complete blood counts, liver biochemical tests and HCV RNA. Patients becoming HCV RNA negative by week 12 will be considered on-treatment responders, continue therapy to week 24, and be monitored thereafter for another 24 weeks. Patients who do not become HCV RNA negative by week 12 as well as patients who relapse after therapy will be retreated with 180 micrograms of peginterferon weekly and 800 mg of ribavirin for another 48 weeks.
The primary outcome will be sustained loss of HCV RNA at 24 weeks after low- or standard-dose combination therapy. Secondary outcomes include viral kinetics and side effects. Because of preliminary results in the initial 31 patients enrolled in this study, the dose of peginterferon was changed from 90 to 180 micrograms weekly for the remaining 29 patients to be enrolled, allowing for a direct comparison of efficacy, viral kinetics and side effects of standard- vs low-dose peginterferon therapy.
This study will evaluate the relative efficacy and safety of the standard versus lower doses of peginterferon with ribavirin in patients with chronic hepatitis C and HCV genotype 2 or 3.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's enrollment of 58 is below the median of 100 across 1,886 interventional studies indexed under Hepatitis A.
Browse Hepatitis A studies →National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is the lead sponsor of 529 studies on the registry; 54 are open to participants now.
Of its 79 completed or terminated interventional studies of FDA-regulated products, 50 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Age above 18 years, male or female.
Presence of anti-HCV in serum.
Positive HCV RNA determination in serum.
HCV genotype 2 or 3 as determined by Inno LiPa assay or by direct sequencing. Patients with mixed genotypes will not be eligible if they have genotypes other than 2 or 3.
Written informed consent.
EXCLUSION CRITERIA:
Previous treatment with interferon alpha or peginterferon.
Decompensated liver disease, as marked by bilirubin greater than 4 mg/dL, albumin less than 3.0 g/dL, prothrombin time greater than 2 sec prolonged, or history of bleeding esophageal varices, ascites or hepatic encephalopathy.
Patients with ALT levels greater than 1000 U/L (greater than 25 times ULN) will not be enrolled but may be followed until three determinations are below this level.
Pregnancy or, in women of child-bearing potential or in spouses of such women, inability to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicidal, or birth control pills, or an intrauterine device.
Significant systemic or major illnesses other than liver disease, including congestive heart failure, renal failure (creatinine clearance less than 50 ml/min), organ transplantation, serious psychiatric disease not controlled by psychotropic agents, and angina pectoris.
Evidence of coronary artery disease or cerebral vascular disease, including abnormalities on exercise stress testing in patients with defined risk factors who will be screened for evidence of underlying coronary artery disease.
Pre-existing, severe bone marrow compromise; anemia (hematocrit less than 30%), neutropenia (less than 1000 neutrophils/microliter) or thrombocytopenia (less than 70,000 cells/microliter).
History of hemolytic anemia.
Evidence of another form of liver disease in addition to hepatitis C (for example hepatitis B, autoimmune liver disease, Wilson's disease, alcoholic liver disease).
Active substance abuse, such as alcohol, inhaled or injection drugs within the previous six months.
Evidence of hepatocellular carcinoma: either alfa-fetoprotein (AFP) levels greater than 50 ng/ml (normal less than 9 ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.
Clinical gout.
HIV infection.
Quiescent or active, serious autoimmune disease such as lupus erythematosus, ulcerative colitis, Crohn's disease or rheumatoid arthritis that in the opinion of the investigators might be exacerbated by therapy with alfa interferon.
The use of immunosuppressive medications, including corticosteroids in doses of 10 mg of prednisone or its equivalent and higher.
Patients receive a lower dose of peginterferon alfa-2a (90 mcg per week) and standard dose of ribavirin (800 mg/d) for chronic hepatitis C, genotype 2/3, for 24 weeks.
Drug: Peginterferon alfa-2a · Drug: Ribavirin
Patients receive the standard, recommended doses of peginterferon alfa-2a (180 mcg per week) and ribavirin (800 mg/d) for chronic hepatitis c, genotype 2/3, for 24 weeks.
Drug: Peginterferon alfa-2a · Drug: Ribavirin
Peginterferon alfa-2a 90 mcg/week
Also known as: Pegasys
180 mcg/week
Also known as: Pegasys
800 mg/day
Also known as: Copegus
Virological Response (Intention to Treat)
Virological response category. Sustained virological response (SVR) is defined as negative serum HCV RNA at least 6 months after the end of treatment. Non-response is defined as serum HCV RNA positivity on week 12 of treatment. Breakthrough/relapse is defined as HCV RNA becoming negative and subsequently positive on treatment or after treatment is stopped.
Time frame: 6 months after stopping therapy
Virological Response Category (Per Protocol)
Virological response category. Sustained virological response (SVR) is defined as negative serum HCV RNA at least 6 months after the end of treatment. Non-response is defined as serum HCV RNA positivity on week 12 of treatment. Breakthrough/relapse is defined as HCV RNA becoming negative and subsequently positive on treatment or after treatment is stopped.
Time frame: 6 months after therapy
First Phase Decline in Logarithm of HCV RNA Level
The 1st phase decline is defined as the log difference between baseline HCV RNA level and the level on day 2 of treatment (see Neumann et al, Science, 1998).
Time frame: 2 days
Slope of Second Phase Decline in HCV Levels
The 2nd phase slope is defined as the slope of the logarithmic viral levels from week 1 to week 4 of treatment (see Neumann et al, Science, 1998).
Time frame: day 7 to day 28
Time to Negativity
Time from treatment initiation to the first negative HCV RNA test during treatment
Time frame: 24 weeks
Between Dec 2003 and Dec 2004, 31 patients were enrolled into the low-dose group and were treated with peginterferon alfa-2a 90ug/week and ribavirin 400 mg/twice daily for 24 week. From Feb 2005, all subsequent patients were enrolled into a standard-dose group and treated for 24 weeks with the doses of the approved regimen.
| Milestone | Low Dose Group | Standard Dose Group |
|---|---|---|
| Started | 31 | 27 |
| Completed | 30 | 27 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
Virological response category. Sustained virological response (SVR) is defined as negative serum HCV RNA at least 6 months after the end of treatment. Non-response is defined as serum HCV RNA positivity on week 12 of treatment. Breakthrough/relapse is defined as HCV RNA becoming negative and subsequently positive on treatment or after treatment is stopped.
| participants | Low Dose Group | Standard Dose Group |
|---|---|---|
| Sustained Virological Response (SVR) | 19 | 21 |
| Relapse/breakthrough | 7 | 2 |
| Nonresponse | 3 | 1 |
| Treatment stopped for adverse event | 0 | 3 |
| Lost to follow-up | 1 | 0 |
The 1st phase decline is defined as the log difference between baseline HCV RNA level and the level on day 2 of treatment (see Neumann et al, Science, 1998).
| logIU/mL | Low Dose Group | Standard Dose Group |
|---|---|---|
| First Phase Decline in Logarithm of HCV RNA Level | 1.15 ± 0.88 | 2.20 ± 1.14 |
Virological response category. Sustained virological response (SVR) is defined as negative serum HCV RNA at least 6 months after the end of treatment. Non-response is defined as serum HCV RNA positivity on week 12 of treatment. Breakthrough/relapse is defined as HCV RNA becoming negative and subsequently positive on treatment or after treatment is stopped.
| participants | Low Dose Group | Standard Dose Group |
|---|---|---|
| SVR | 19 | 20 |
| Relapse/breakthrough | 7 | 2 |
| Nonresponse | 2 | 1 |
The 2nd phase slope is defined as the slope of the logarithmic viral levels from week 1 to week 4 of treatment (see Neumann et al, Science, 1998).
| logIU/mL | Low Dose Group | Standard Dose Group |
|---|---|---|
| Slope of Second Phase Decline in HCV Levels | 1.14 ± 0.69 | 1.39 ± 0.64 |
Time from treatment initiation to the first negative HCV RNA test during treatment
| days | Low Dose Group | Standard Dose Group |
|---|---|---|
| Time to Negativity | 42 (32 to 51) | 28 (19 to 37) |
Collected over 72 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose Group | — | 0/30 (0%) | 2/30 (6.7%) |
| Standard Dose Group | — | 3/27 (11.1%) | 1/27 (3.7%) |
| Event | Low Dose Group | Standard Dose Group |
|---|---|---|
| Melanoma and deathSkin and subcutaneous tissue disorders | 0/30 | 1/27 |
| Mastoiditis complicated by myocardial infarction, heart failure, coronary bypass surgery and deathCardiac disorders | 0/30 | 1/27 |
| Heroin overdose leading to deathSocial circumstances | 0/30 | 1/27 |
| Event | Low Dose Group | Standard Dose Group |
|---|---|---|
| Severe hemolysis requiring transfusionBlood and lymphatic system disorders | 0/30 | 1/27 |
| Sarcoidosis developmentBlood and lymphatic system disorders | 1/30 | 0/27 |
| Atrial fibrillation (off treatment),Cardiac disorders | 1/30 | 0/27 |
| Age Continuous(years) | Low Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| Mean | 48 (29 to 62) | 47 (26 to 69) | 48 (26 to 69) |
| Sex: Female, Male(Participants) | Low Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| Female | 15 | 14 | 29 |
| Male | 15 | 13 | 28 |
| Race/Ethnicity, Customized(participants) | Low Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| Caucasian | 26 | 20 | 46 |
| Asian | 2 | 5 | 7 |
| Hispanic | 1 | 0 | 1 |
| African-American | 1 | 2 | 3 |
| Region of Enrollment(participants) | Low Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| United States | 30 | 27 | 57 |
| ALT(U/L) | Low Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| Mean | 91 ± 69 | 97 ± 85 | 94 ± 77 |
| HCV RNA(log IU/mL) | Low Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| Mean | 6.3 ± 0.82 | 5.9 ± 1.02 | 6.1 ± 0.92 |
| Genotype(participants) | Low Dose Group | Standard Dose Group | Total |
|---|---|---|---|
| HCV Genotype 2 | 21 | 13 | 34 |
| HCV Genotype 3 | 9 | 14 | 23 |
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)